


## Enrasentan

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No. :         | 167256-08-8  |
| Formula:          | C <sub>29</sub> H <sub>30</sub> O <sub>8</sub>   |
| Molecular Weight: | 506.54   |
| Storage:          | Store at low temperature<br>Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br><small>Actual storage temperature shall be subject to the COA.</small> |



## Biological Description

|                            |  |
|----------------------------|--|
| Description                | Enrasentan (sb-217242) is a mixed antagonist of ET(A) and ET(B) receptors that reduces blood pressure, prevents cardiac hypertrophy, and protects myocardial function. |
| Targets(IC <sub>50</sub> ) | Endothelin Receptor  |

## Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 1.9742 mL | 9.8709 mL | 19.7418 mL |
| 5 mM  | 0.3948 mL | 1.9742 mL | 3.9484 mL  |
| 10 mM | 0.1974 mL | 0.9871 mL | 1.9742 mL  |
| 50 mM | 0.0395 mL | 0.1974 mL | 0.3948 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Cosenzi A, et al. Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia. *J Cardiovasc Pharmacol*. 2002 Apr;39(4):488-95.

Cosenzi A. Enrasentan, an antagonist of endothelin receptors. *Cardiovasc Drug Rev*. 2003 Spring;21(1):1-16. Review. PubMed PMID: 12595914.

Cosenzi A, Bernobich E, Bonavita M, Bertola G, Trevisan R, Bellini G. Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia. *J Cardiovasc Pharmacol*. 2002 Apr;39(4):488-95. PubMed PMID: 11904522.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. *J Cardiovasc Pharmacol*. 2001 Oct;38(4):606-17. PubMed PMID: 11588531.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481